Source: Eur Respir J, 58 (2) 2101076; 10.1183/13993003.01076-2021
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
José L. Izquierdo, Joan B. Soriano. Biologics may have a beneficial effect in asthma patients with COVID-19. Eur Respir J, 58 (2) 2101076; 10.1183/13993003.01076-2021

Member's Comments

No comment yet.

Related content which might interest you: Education of the patients and its effect in asthma management Source: Eur Respir J 2003; 22: Suppl. 45, 371s Year: 2003 The impact of COVID-19 on patients with asthma Source: Eur Respir J, 57 (3) 2003142; 10.1183/13993003.03142-2020 Year: 2021 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Modelling the beneficial impact of inhaled corticosteroids on health outcomes among COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 Effect of asthma and asthma medication on the prognosis of patients with COVID-19 Source: Eur Respir J, 57 (3) 2002226; 10.1183/13993003.02226-2020 Year: 2021 Study of antioxidant use in patients with asthma exacerbations Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Anti-inflammatory effect of an additional therapy with Montelukast on steroid-dependent children with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 492s Year: 2001 The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 The effect of long-term treatment with erdosteine on moderate or severe COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 Study of some inflammatory markers in children with moderate persistent bronchial asthma before and after therapy with inhaled corticosteroids Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013 The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment Source: International Congress 2016 – Translational studies in lung disease Year: 2016